InterMune Positive On Pirfenidone Despite Mixed Study Results
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
InterMune was left with a mixed bag when it released its major Phase III program of pirfenidone in idiopathic pulmonary fibrosis, which yielded conflicting primary endpoint results. But the company thinks there are enough tricks in that bag to win FDA approval
You may also be interested in...
InterMune's Pirfenidone Gets Advisory Committee Date; Panel Will Weigh Unmet Need Against Mixed Results
FDA has granted the drug priority review status due to the unmet medical need it addresses.
Statistics Bedeviled But Did Not Derail Cymbalta Fibromyalgia Approval
Lilly ran into one review issue with its fibromyalgia NDA for Cymbalta (duloxetine) because it did not adhere to a "well established policy" of the FDA division responsible for analgesic drugs regarding imputation of missing data, a recurring statistical issue in pain drug reviews, review documents show
InterMune’s Idiopathic Pulmonary Fibrosis Push Continues As Actimmune Sales Slump
Data support gambling on experimental pirfenidone against “incredibly complex” disease, chief scientific officer tells “The Pink Sheet” DAILY.